UCB to comarket Elan Frova
Executive Summary
UCB will contribute 475 primary care sales reps to comarket Elan migraine therapy Frova (frovatriptan) under agreement announced March 28. Companies plan for second quarter 2002 launch. Neurologists will be detailed with Elan and UCB combined sales force of 265 reps under seven-year agreement. Frova was approved Nov. 8 (1"The Pink Sheet" Nov. 12, 2001, p. 35)...